Top 50 Ai For Genomics in Asia

GENOBOTICS AI provides a cloud‑native platform that applies deep‑learning models to automatically annotate genomic variants and predict their therapeutic relevance. Users upload standard formats (VCF, BAM, FASTQ) and receive batch‑processed results within minutes via RESTful APIs or an interactive dashboard, with end‑to‑end encryption and HIPAA/GDPR compliance for pharmaceutical, biotech, and academic precision‑medicine teams.

MEDHINI is a generative AI-powered software platform that provides genomics-based multimodal solutions for healthcare diagnostics, focusing on areas such as antimicrobial resistance and virtual clinical trials. The platform enhances diagnostic accuracy and accessibility in pulmonology, neurology, nephrology, cardiology, and oncology, addressing the need for affordable healthcare solutions with measurable social impact.

Neurolov offers a cloud‑native platform that runs curated machine‑learning models on genomics, transcriptomics, proteomics and phenotypic data to produce predictive biomarkers, pathway activity scores, and compound efficacy forecasts. The service automates data ingestion, preprocessing, feature engineering and model inference, delivering results through interactive dashboards and API endpoints for integration with LIMS and downstream analysis. By providing a managed, scalable compute environment with versioned model registries and GxP/HIPAA compliance, it shortens the turnaround time for drug discovery teams.

Utilizes generative AI to design de novo genes and proteins that integrate multiple biological functions into compact therapeutic molecules. This approach addresses unmet medical needs by enabling the development of highly effective treatments with improved efficiency and specificity.

3BIGS utilizes bio big data and AI-driven platforms to analyze next-generation sequencing (NGS) data, identifying patterns, mutations, and biomarkers for drug discovery and healthcare insights. The company addresses the challenge of extracting actionable information from vast biological datasets, accelerating the development of targeted therapies and improving patient outcomes.

The startup develops a bioinformatics platform that employs artificial intelligence to analyze fetal cell-free DNA extracted from maternal blood samples during the first trimester. This technology enables early detection of genetic disorders, including point mutations and chromosomal anomalies, in a non-invasive and cost-effective manner.

MNDL Bio utilizes AI-driven computational models to optimize gene expression for recombinant protein production, significantly enhancing yield and reducing costs. The platform replaces traditional trial-and-error methods with precise, data-driven strain engineering, enabling faster time-to-market and improved sustainability in biotech and foodtech applications.

Engine Biosciences utilizes machine learning and high-throughput biology to identify genetic interactions within complex disease networks, enabling the development of targeted therapeutics and biomarkers for specific patient populations. This approach significantly accelerates the research and development process for new medical therapies, reducing costs and improving clinical outcomes for a range of solid tumors.

The startup develops medical artificial intelligence devices that utilize big data collection, processing, and gene mutation analysis to enhance health management and disease prevention. By enabling real-time analysis of endoscopic images, the technology provides critical insights to medical practitioners, improving treatment strategies and patient outcomes.

Helix integrates genomic data into healthcare systems, enabling health organizations to utilize population genomics for personalized diagnosis, treatment, and prevention. By providing actionable genetic insights, Helix enhances patient outcomes and reduces costs across medical research and clinical care.

Algorithmic Biologics develops a software platform that enhances molecular testing workflows through advanced computational applications, including compression algorithms for next-generation sequencing. This technology significantly reduces library preparation costs by over 60%, making molecular diagnostics more accessible and efficient for healthcare providers.

Provides genetic testing services using next-generation sequencing and proprietary algorithms to detect hereditary diseases, cancer mutations, and genetic disorders. These tests enable early diagnosis, personalized treatment plans, and risk assessment, improving health outcomes for patients in prenatal, oncology, and chronic disease contexts.

Eleven Therapeutics utilizes synthetic chemistry and AI algorithms to develop RNA therapeutics that optimize safety, efficiency, and duration of effect. Their platform maps the vast chemical space of RNA molecules, addressing the need for precise and effective therapeutic solutions in the rapidly evolving field of RNA-based medicine.

UMAMI Bioworks develops a scalable platform for cultivating seafood from endangered, threatened, or protected species using genomics, stem cell biology, and machine learning. This approach addresses the critical issue of overfishing and oceanic degradation by providing a sustainable alternative to traditional fishing methods.

4baseCare develops precision oncology solutions utilizing next-generation sequencing and comprehensive genomic profiling to identify specific cancer mutations in patients. Their technology addresses the need for personalized treatment options by providing tailored insights that enhance therapeutic decision-making for cancer care in the Indian population.

Haystack develops a next-generation genomic testing platform that utilizes next-generation sequencing (NGS) technology to rapidly identify over 1,200 pathogens associated with infectious diseases, including antibiotic resistance profiles. The platform delivers results in under 12 hours, enabling clinicians to make timely and informed treatment decisions for patients at risk of sepsis and other life-threatening infections.

This biotechnology company utilizes artificial intelligence to cultivate and evolve proteins essential for bio-products, enhancing the efficiency of medical research. By providing reliable and rapid access to these proteins, the company addresses the need for improved medical services in the healthcare sector.

Protai utilizes machine learning and mass spectrometry-derived proteomics data to create a vertically integrated platform for drug discovery. This technology enables precise targeting of complex disease drivers, facilitating the identification of novel therapeutic targets and improving the development of effective treatments.

The startup has developed an epigenetics platform that analyzes cancer patients, specifically focusing on Asian cancers, using epigenomic predictive models to generate actionable insights for treatment decisions. This technology enables clinicians to tailor personalized medicine strategies for advanced cancers, improving patient care through data-driven approaches.

Igentify Ltd offers a digital platform that streamlines genomic workflows, enabling patients, laboratories, and healthcare providers to access and interpret genetic information securely. This solution addresses the challenge of inefficient genetic data management, enhancing the effectiveness of preventive healthcare services.

Biomica develops microbiome-based therapeutics using a proprietary computational platform that integrates metagenomics sequencing and AI to identify optimal microbial candidates for treating cancer, immune-mediated, and infectious diseases. The company addresses the challenge of unmet medical needs by maximizing therapeutic efficacy while minimizing adverse effects through carefully curated microbial consortia.

Apeiron Therapeutics develops biomarker-driven small molecule therapies for cancer using structure-based, AI-driven drug design. The company focuses on creating targeted treatments for solid tumors with specific genetic deletions, addressing significant gaps in current cancer therapies.

Provides an AI-powered platform, MoleculeGEN, for de novo drug design and antibody generation, leveraging deep learning and biophysics to create novel small molecules and antibodies tailored to specific disease targets. This approach addresses the challenges of traditional drug discovery by automating hit generation, lead optimization, and toxicity prediction, enabling faster development of treatments for diseases with high unmet medical needs.

This startup offers whole genome sequencing and genetic testing services to identify health risks and inform personalized medicine. They provide genetic counseling and bioinformatics tools to patients and healthcare providers for accurate genetic analysis.

ConnectingDNA is an AI-powered DNA wellness marketplace that provides personalized, science-backed health recommendations based on user DNA reports. The platform interprets natural language queries to offer tailored guidance across nutrition, fitness, and mental health, connecting users with vetted wellness providers for DNA-informed programs.

Geneyx provides DNA and RNA data analysis and interpretation for whole genome sequencing (WGS), whole exome sequencing (WES), gene panels, and microarrays, enabling rapid transformation of raw genetic data into clinical reports. The platform enhances diagnostic accuracy and efficiency, aiming to eliminate undiagnosed diseases by increasing the diagnostic yield and reducing turnaround times for genetic testing.

MGI Tech develops genetic sequencers and lab automation tools that enhance genomic analysis and streamline sample preparation processes in life sciences. Their technology addresses the need for efficient, high-throughput sequencing and data management, enabling precise diagnostics and research in healthcare and agriculture.

This startup develops a platform that integrates advanced genomic technologies for diagnostics, prognostics, and therapeutic development. It offers genetic testing and counseling to diagnose and treat rare diseases, enabling personalized care for patients.

This deep tech company leverages digital biomarkers, blood biochemicals, genomics markers, machine learning, and deep learning to provide personalized, evidence-based Ayurvedic health and wellness solutions. It addresses the lack of data-driven frameworks in traditional Ayurveda, enabling P5 medicine through a scientific approach.

The startup develops an AI bioinformatics platform that utilizes big data analytics and predictive modeling to streamline the identification and validation of drug targets. By simplifying complex biomedical data networks, the platform enables biochemists to gain actionable insights for target identification and drug repurposing.

The startup develops a genotyping and sequencing platform that translates genetic data into clinical applications, enabling healthcare providers to make informed treatment decisions. This technology enhances patient care and biomedical research by improving the understanding and management of diseases.

IMBdx offers a liquid biopsy platform that combines artificial intelligence and genomic analysis for early cancer detection and ongoing patient monitoring. Their technology enables precise screening and monitoring of various cancer types through simple blood tests, improving treatment planning and patient outcomes.

Cariva develops AI-enabled personalized healthcare solutions, including modular building block systems for health app development and a data network that connects various healthcare sources and devices. Their ONCO+ service provides genetic testing for cancer risk, facilitating early detection and surveillance for patients and their families.

Zene is a genome data analysis platform that offers high-precision genomic analysis services using saliva samples to provide individuals with insights into their genetic traits. The platform also supports health insurance organizations by delivering actionable genomic information to reduce medical costs and enhance employee health management.

Foresee Genomics offers an integrated next-generation sequencing (NGS) platform that makes advanced genomic analysis accessible to smaller laboratories. Their solution combines optimized protocols, specialized reagents, and user-friendly bioinformatics tools to reduce costs and lab space requirements. This empowers labs to perform high-accuracy genomic analysis for improved diagnostics and precision medicine.

Vision Medicals specializes in gene technology and precision medicine to enhance patient-specific treatment strategies. The company focuses on utilizing genomic data to improve diagnostic accuracy and tailor therapies for genetic disorders, ultimately increasing treatment efficacy.

Massive Bio offers an AI‑powered platform that consolidates clinical trial data, drug pipelines, and genomic test results into a searchable hub. Its machine‑learning engine matches patients’ clinical profiles and biomarkers to generate real‑time eligibility scores and treatment recommendations, delivered via a secure physician dashboard and patient mobile app.

Massive Bio is an AI-powered oncology platform that matches cancer patients with over 19,000 clinical trials worldwide by analyzing their medical history and genomic profiles. The platform facilitates access to trials for patients regardless of their location or financial situation, while providing pharmaceutical companies with a streamlined way to connect with potential participants.

Logomix offers a Geno-Writing platform that enables precise engineering of megabase-scale genomic sequences in human cells, facilitating the creation of custom cell types with specific functions. This technology addresses the challenges of immune rejection and functional integration in cell therapies, enhancing the development of advanced regenerative medicine solutions.

Psifas is developing a platform that integrates longitudinal medical records with whole genome sequencing data to facilitate targeted medical research. This approach enables early disease detection and intervention, improving health outcomes by providing researchers with comprehensive, anonymized datasets for analysis.

Genz develops AI algorithms for genomic data analysis to facilitate personalized treatment plans for women with breast cancer. By leveraging advanced data analytics, the company aims to enhance the precision of therapeutic interventions tailored to individual genetic profiles.

NetTargets utilizes AI-enhanced systems biology and mathematical modeling to provide interpretable predictions for drug discovery, significantly reducing the risk of clinical trial failures. By simulating causal biological networks, the company helps identify effective treatment strategies and optimize patient selection, addressing the high failure rates in drug development.

Molcure offers an AI-driven platform that combines a proprietary large‑language model trained on over one billion antibody and peptide sequences with integrated directed‑evolution and next‑generation sequencing workflows. The system generates de novo candidates and optimizes existing leads using deep‑learning and physics‑based simulations, delivering faster hit discovery, higher affinity predictions, and seamless integration via cloud analytics and API endpoints for pharma, biotech, and CRO R&D teams.

The startup provides genomic reports tailored for the Indian population by integrating genomic, physiological, and physical data through machine learning algorithms. This approach enables individuals to understand their genetic predispositions and make informed decisions about their diet and lifestyle to mitigate the risk of lifestyle and clinical disorders.

ProPhet utilizes AI and machine learning to predict protein dynamics and interactions with drug candidates, enabling the identification of small molecules for hard-to-target proteins. This approach addresses the challenge of discovering therapeutics for diseases previously deemed undruggable, enhancing the efficiency and accuracy of early-stage drug discovery.

This startup provides an AI-powered blockchain platform for decentralized science, specifically focused on genomics. It offers researchers access to clean, labeled, and organized genetic profiles, accelerating the development of personalized, data-driven medical solutions and reducing time-to-market for genomics-based AI applications.

BiotaX utilizes AI-driven computational biology to construct natural microbial communities tailored for specific functions in health, food, agriculture, and climate applications. The platform addresses the challenge of harnessing the vast diversity of uncultured bacteria to develop effective microbial solutions for various industries.

The startup develops protein degradation drugs using an AI-enabled platform to identify and target disease-related proteins in cancer, neurodegenerative, and aging-related diseases. This approach provides researchers and pharmaceutical companies with a new class of therapeutics that can overcome drug resistance in life-threatening conditions.

PhenoTA utilizes advanced AI algorithms to analyze blood cell data from routine blood tests, providing detailed insights into individual health conditions. This technology enhances medical decision-making by delivering precise, actionable information that can lead to earlier diagnosis and improved patient outcomes.

Kobiolabs develops microbiome-based therapeutics using its Smartiome® platform, which employs AI-driven multi-omics analysis to create targeted treatments for immune, metabolic, and neurological disorders. By harnessing the complex interactions of the human microbiome, the company aims to address various health conditions linked to microbial imbalances.